No Data
EU to Require Additional Cancer Risk Labeling on CAR T Therapies
Express News | 2Seventy Bio Inc : Goldman Sachs Cuts Target Price to $2 From $5
Top Midday Decliners
Sprinklr (CXM) shares sank 16% after the company lowered its revenue outlook amid better-than-expected Q1 performance. Barclays cut its price target to $11 from $17 while maintaining its overweight ra
Goldman Cuts 2seventy Bio to Neutral, Cites Competition Concerns
Goldman Sachs Downgrades 2seventy Bio(TSVT.US) to Sell Rating, Cuts Target Price to $2
Goldman Sachs analyst Salveen Richter downgrades $2seventy bio(TSVT.US)$ to a sell rating, and adjusts the target price from $5 to $2.According to TipRanks data, the analyst has a success rate of 47.1
2seventy Bio to Participate in Upcoming Investor Conferences
2seventy bio, Inc. (NASDAQ:TSVT) announced today that members of the management team will present at the following upcoming investor conferences: TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO
JESSE JAMES8832 : quite a bit better than expected right?
JESSE JAMES8832 : 13.9m was the prediction
TrytosaveabitOP JESSE JAMES8832: I believe so yes?
TrytosaveabitOP JESSE JAMES8832: That rings a bell!
JESSE JAMES8832 : damn i thought this would do much better... short attack?
View more comments...